Volume 199, Issue 5, Pages (May 2018)

Slides:

Advertisements

Similar presentations

Randomized Trial of Percutaneous Tibial Nerve Stimulation Versus Sham Efficacy in the Treatment of Overactive Bladder Syndrome: Results From the SUmiT.

Advertisements

Maria Carmen Mir, Cesar Ercole, Andrew Stephenson

Volume 165, Issue 5, Pages (May 2001)

MP60-03 PROSTATE CANCER IN THE ELDERLY

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Benjamin Herrick, Cameron Banga, Michael Phelps, Ronald Yap

Socializing Individualized T-Cell Cancer Immunotherapy

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

A Novel Link between Inflammation and Cancer

Volume 71, Issue 2, Pages (February 2017)

Small but Mighty: Selected Commensal Bacterial Species Determine the Effectiveness of Anti-cancer Immunotherapies Jose R. Conejo-Garcia, Melanie R. Rutkowski

Primary Small Cell Carcinoma Arising from a Bladder Diverticulum

Figure 1 Cellular processes involved in cancer development

Bladder Lymphoma The Journal of Urology

Seminal Vesicle Invasion by Adenocarcinoma of the Prostate

Yolk Sac Tumor of the Testis

Volume 71, Issue 6, Pages e171-e172 (June 2017)

Bladder Cancer: Management and Future Directions

Oncocytoma of the Kidney

Volume 195, Issue 4, Pages e288-e289 (April 2016)

Paratesticular Serous Papillary Borderline Tumor

The Path(way) Less Traveled: A Pathway-Oriented Approach to Providing Information about Precision Cancer Medicine on My Cancer Genome Alexandria D. Taylor,

Volume 189, Issue 1, Pages (January 2013)

Renovascular Hypertension after Laparoscopic Partial Nephrectomy

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Pseudohyperplastic Adenocarcinoma of the Prostate

Radiotherapy Complements Immune Checkpoint Blockade

Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma Darshil J. Shah, MD, MPH, Roxana S. Dronca,

Nat. Rev. Endocrinol. doi: /nrendo

Figure 6 Common signalling mechanisms, pathways,

Megan E. Daly, MD, Arta M. Monjazeb, MD, PhD, Karen Kelly, MD

Cell signaling and cancer

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Tumor Evolution: A Problem of Histocompatibility

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

JAK inhibitors in dermatology: The promise of a new drug class

Figure 13 Proposed management of bladder cancer with variant histology

Andrew Blauvelt, Mark G. Lebwohl, Robert Bissonnette

Short-Bowel Syndrome Clinical Gastroenterology and Hepatology

Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer

Figure 1 The role of CTLA4 and PD1 in T cell activation

Targets for immunotherapy of liver cancer

Figure 2 Site of action of checkpoint inhibitors and agonists being

Volume 45, Issue 4, Pages (October 2006)

Eukaryotic Transcription Activation: Right on Target

Figure 1 A hierarchy of steps need to be

Nat. Rev. Endocrinol. doi: /nrendo

The Other Face of Chimeric Antigen Receptors

Johan Botling, MD, PhD, Martin Sandelin, MD, PhD

MicroRNAs in Memory Processing

Figure 1 Mechanisms of action of immunotherapy modalities

Proteins in Plant Brassinosteroid Signaling

Prognostic Factors in Non–Muscle-Invasive Bladder Tumors

Are calcineurin inhibitors-free regimens ready for prime time?

Cancer Evolution during Immunotherapy

Andy J. Minn, E. John Wherry Cell

Michele De Palma, Rakesh K. Jain Immunity

Volume 95, Issue 4, Pages (April 2019)

Sterile Inflammation Fuels Gastric Cancer

Therapy of Alopecia Areata: On the Cusp and in the Future

Distribution of immune checkpoint in tumor cells and immune microenvironment. CTLA-4, cytotoxic T lymphocyte antigen-4; MHC, major histocompatibility complex;

Releasing the Brakes on Cancer Immunotherapy

KEYNOTE-024: Unlocking a pathway to lung cancer cure?

Jamie E. McInturff, Robert L. Modlin, Jenny Kim

Co-opted integrin signaling in ErbB2-induced mammary tumor progression

Figure 4 Molecular signalling and immunological

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

(A) Lymph node priming phase: recognition of major histocompatibility complex (MHC) by T-cell receptor (TCR), coactivating CD 28/B7 pathway activation.

Stable IL-10: A New Therapeutic that Promotes Tumor Immunity

Presentation transcript:

Volume 199, Issue 5, Pages 1129-1142 (May 2018) Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma Arlene O. Siefker-Radtke, Andrea B. Apolo, Trinity J. Bivalacqua, Philippe E. Spiess, Peter C. Black The Journal of Urology Volume 199, Issue 5, Pages 1129-1142 (May 2018) DOI: 10.1016/j.juro.2017.10.041 Copyright © 2018 American Urological Association Education and Research, Inc. Terms and Conditions

Figure 1 Basal and luminal subtypes of MIBCs. PPARG, peroxisome proliferator-activated receptor γ. ESR1, estrogen receptor 1. STAT3, signal transducer and activator of transcription 3. TP63, tumor protein 63. Reprinted by permission from: Choi W et al: Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol 2015; 11: 400. The Journal of Urology 2018 199, 1129-1142DOI: (10.1016/j.juro.2017.10.041) Copyright © 2018 American Urological Association Education and Research, Inc. Terms and Conditions

Figure 2 Urothelial carcinoma specific antitumor immunity cycle and role of CTLA-4 and PD-1/PD-L1 pathways. MHC-I, major histocompatibility complex class I. TCR, T-cell receptor. Adapted with permission from: Kim JW et al: Emerging immunotherapies for bladder cancer. Curr Opin Oncol 2015; 27: 191. The Journal of Urology 2018 199, 1129-1142DOI: (10.1016/j.juro.2017.10.041) Copyright © 2018 American Urological Association Education and Research, Inc. Terms and Conditions